Sector News

After years of setbacks, Vical to slash jobs, Astellas drug work

January 31, 2018
Life sciences

Vical has been hit with trial flop after trial flop, from cancer vaccines and herpes vaccines to just last week a cytomegalovirus (CMV) vaccine licensed from Astellas.

Now, with more than a touch of inevitability, the micro-cap biotech is letting go of around half of its workforce, trimming the number down from 74 staffers to a mere 34, in an attempt to save cash in the longer term.

This will also allow it to “focus its efforts on VL-2397, its antifungal drug product candidate which is entering a pivotal phase 2 clinical trial in the first quarter of 2018, and on completing its phase 2 HSV-2 clinical trial,” according to a statement.

Not included is this focus is the Astellas CMV program; earlier this month, Vical announced this vaccine, dubbed ASP0113, didn’t show a significant improvement in overall survival or reduction in CMV end-organ disease, missing the phase 3 trial’s primary composite endpoint, while also missing its secondary endpoints.

This is the second failure for the med after it also flopped in a midstage kidney transplant test. And it’s curtains for Vical’s work here: “The company is terminating all activities related to the ASP0113 program licensed to Astellas Pharma,” it said.

“We have carefully evaluated our organization and priorities and are restructuring to extend our cash runway to ensure that our promising HSV-2 vaccine candidate and VL-2397 antifungal drug product candidate is adequately resourced to maximize shareholder value,” said Vijay Samant, Vical’s president and CEO.

“This has been a very difficult process and we regret the impact this business decision has on our departing employees. We greatly appreciate the hard work and commitment they have shown Vical over the years and wish them the very best in their future endeavors.”

Last night, Vical’s shares were marginally up after hours, although its market cap is just $18 million. It ended 2017 with cash and investments of around $60 to $65 million, it says, and expects this to get it to the end of next year.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).